KIMBERLY ALDIS: Open Payments
NPI 1265903447 · HUNTSVILLE, AL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,438 in 108 payments from 35 companies in 2025. Trend: 2023 $2,114 · 2024 $2,484 · 2025 $2,438
Food & beverage: $2,244Education: $194
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 17 | $351 |
| Janssen Biotech, Inc. | 13 | $340 |
| Genentech USA, Inc. | 7 | $150 |
| ABBVIE INC. | 5 | $146 |
| AstraZeneca Pharmaceuticals LP | 6 | $135 |
| Merck Sharp & Dohme LLC | 5 | $126 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $120 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 4 | $103 |
| SOBI, INC | 6 | $101 |
| Incyte Corporation | 3 | $72 |
Products named: RYBREVANT, LUTATHERA, IMFINZI, KEYTRUDA, Vonjo, IMBRUVICA, REBLOZYL, KISQALI.
Industry payments across AL — which companies pay providers there.
